The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

NMOSD — Eculizumab, Satralizumab, and Inebilizumab Targeted Therapy

Approved monoclonal antibody therapies for aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder, targeting complement component C5 (eculizumab, ravulizumab), interleukin-6 receptor (satralizumab), and CD19 B cells (inebilizumab) to prevent relapses with high efficacy and tolerable safety.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Nöroloji department. Book Appointment →

What is NMOSD — Eculizumab, Satralizumab, and Inebilizumab Targeted Therapy?

Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune demyelinating disease of the central nervous system, mostly mediated by aquaporin-4-IgG antibodies attacking astrocytes, with myelin oligodendrocyte glycoprotein-IgG (MOGAD) representing a related but distinct entity treated differently.

Three monoclonal antibody therapies have been approved for AQP4-IgG-positive NMOSD: eculizumab (and its longer-acting analogue ravulizumab) targeting complement C5, satralizumab targeting interleukin-6 receptor, and inebilizumab targeting CD19 to deplete B cells; each demonstrated significant relapse reduction in pivotal phase 3 trials.

Treatment selection considers antibody status (AQP4-IgG positive required for full benefit), pregnancy plans, infection risk, route of administration (intravenous vs subcutaneous), dosing frequency, comorbidities, and prior immunosuppressive therapy, in shared decision-making with the patient.

Symptoms

Optic neuritis with severe vision loss, often bilateral or sequential
Longitudinally extensive transverse myelitis with sensorimotor deficits, sphincter dysfunction, and respiratory compromise
Area postrema syndrome: intractable hiccups, nausea, vomiting
Acute brainstem syndromes, narcolepsy-like features, or symptomatic cerebral syndromes
Relapse pattern with stepwise neurologic disability accumulating over time
Predominance in women, with bimodal age distribution including pediatric and adult-onset forms

Risk Factors

AQP4-IgG seropositivity (95% benefit predictor for current targeted therapies)
Female sex, with peak onset in third to fourth decade and second peak in older adults
Coexistent autoimmune disease (systemic lupus erythematosus, Sjögren syndrome, myasthenia gravis)
Higher relapse risk after stopping immunosuppression, vaccination, or postpartum
Pediatric NMOSD with potentially different course and need for tailored treatment
Asian, African, and Hispanic ancestry with higher disease prevalence in some populations

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • First neurologic event suspicious for NMOSD (severe optic neuritis, longitudinally extensive myelitis, area postrema syndrome) — emergency neurology evaluation with MRI and antibody testing
  • Established NMOSD with relapse despite ongoing therapy — urgent review for high-dose steroids, plasma exchange, and reassessment of maintenance therapy
  • NMOSD patient considering pregnancy, surgery, or vaccination — multidisciplinary planning with neurology, obstetrics, and infectious disease
  • Suspected serious infection on biologic therapy — emergency assessment with attention to encapsulated organisms in eculizumab/ravulizumab patients
  • Long-term monitoring of treatment efficacy, antibody titers, and side effects — neurology center experienced in NMOSD

Treatment Methods

01
Acute attack treatment with high-dose intravenous methylprednisolone (1 g daily for 5 days), with rescue plasma exchange if poor response
02
Eculizumab (intravenous every 2 weeks) or ravulizumab (intravenous every 8 weeks) for AQP4-IgG-positive NMOSD, with meningococcal vaccination prior to therapy
03
Satralizumab (subcutaneous monthly) targeting IL-6 receptor, monotherapy or combined with conventional immunosuppression
04
Inebilizumab (intravenous every 6 months) for B-cell depletion, with monitoring of immunoglobulin levels and infection risk
05
Long-term care: relapse surveillance, MRI, vaccination updates, treatment of comorbidities, multidisciplinary rehabilitation, and shared decision-making about therapy duration and switching

Which Department to Visit?

You can visit our Nöroloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Nöroloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Headache and Migraine

Nöroloji

What you need to know about headache types, migraine attacks, and triggering factors.

Low Back Pain

Nöroloji

Learn about the most common causes of low back pain, risk factors, and appropriate treatment approaches.

Neck Pain and Cervical Disc Herniation

Nöroloji

Learn about the symptoms and treatment options for cervical disc herniation and problems in the neck region.

Epilepsy

Nöroloji

Accurate information about epilepsy, types of seizures, and recommendations for patients and families.

Parkinson Disease

Nöroloji

Parkinson disease is caused by progressive degeneration of dopaminergic neurons and alpha-synuclein accumulation; well-timed therapy substantially improves function and quality of life.

Alzheimer's Disease and Dementia

Nöroloji

Information about early signs, diagnosis, and the care process for Alzheimer's and other types of dementia.

Multiple Sclerosis (MS)

Nöroloji

What is multiple sclerosis, who is at risk, and which treatments are applied?

Stroke

Nöroloji

What is stroke, what are the FAST signs, and why is emergency intervention critical?

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.